A lethal new drug dubbed “gray death” by authorities that is dangerous to even touch with gloves is being eyed in overdose cases across Georgia, Alabama and Ohio. Investigators said the high-potency cocktail — which is comprised of heroin, fentanyl, the elephant tranquilizer carfentanil, and a synthetic opioid called U-47700 — can kill users with a single dose.
A spokeswoman for the agency told the Associated Press that they’ve seen 50 overdoses cases involving gray death over the past three months.
“This is not a drug that you use to get high — if you put this drug into your body you will die, it will kill you,” Clay Hammac, Shelby County Drug Enforcement Task commander, told ABC 33 40.
You don’t know what you’re getting with these things,” Richie Webber, who overdosed on fentanyl-laced heroin in 2014, told The Associated Press.
as informed in
There are 40 deaths related to this form fentanyl patches
Cook County Medical Examiner Dr. Ponni Arunkumar said this year alone there have been 40 deaths related to this fentanyl prototype.
The Cook County Medical Examiner says it’s more powerful then heroin, warning residents the drug is out there, it’s easy to get and it can be fatal almost instantly.
They’ve seen such a dramatic rise in the number of these cases that they’ve issued an alert to first responders and the general public to warn of the dangers of this powerful new drug.
An ER doctor at Stroger Hospital, Dr. Steven Aks said this new fentanyl analog can kill without any early symptoms or warnings.
as informed in Regulators asked the Japanese pharma company to file the drug for ALS after its approval in Korea and Japan.
The drug — which has also been sold for acute ischemic stroke for years in Japan — will now hit the market as Radicava.
For a short time at least, a new subsidiary group set up to sell the drug will have a clear crack at a market that was slated to shrink as the sole branded ALS drug lost revenue to generics.
AB Science’s AB-1010, an oral tyrosine kinase inhibitor, was filed for an approval in Europe last fall.
Patients continued to decline in the 167-patient study reviewed by the FDA, but they weren’t so quick to lose their ability to function.
This content may collect you by Jack Oliver